SecBot SecBot
SECBOTREPLAY Home › Report › LYEL

LYEL · Lyell Immunopharma announced updated safety data from its Phase 1 trial…

Lyell Immunopharma, Inc · PRESS-RELEASE filed Jun 8, 2026 at 06:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 8, 2026 at 06:00 ET

Lyell Immunopharma announced updated safety data from its Phase 1 trial of LYL273 in metastatic colorectal cancer, showing GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% to 10%. The trial was amended to a Phase 1/2 design enabling a potential pivotal single-arm Phase 2 trial, with an End-of-Phase 1 FDA meeting and additional clinical data expected in H2 2026.

  • GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% (without prophylaxis, N=9) to 10% (with prophylaxis, N=10).
  • No Grade ≥3 CRS or ICANS observed in patients receiving GI prophylaxis.
  • Maximum tolerated dose has not yet been determined; dose escalation continues.
  • Phase 1 trial amended to Phase 1/2 design (CARABINER) enabling seamless expansion into a potential pivotal single-arm Phase 2 trial.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access